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Noradrenaline (1-10 gM) inhibited Ca 2 +-induced insulin secretion from electrically permeabilised islets of 
Langerhans with an efficacy similar to that for inhibition of glucose-induced insulin secretion from intact 
islets. The inhibition of insulin secretion from permeabilised islets was blocked by the ~-adrenoreceptor 
antagonist, yohimbine. Adenosine Y,5'-cyclic monophosphate (cAMP) did not relieve the noradrenaline in- 
hibition of Ca 2 +-induced secretion from the permeabilised islets, although noradrenaline did not affect he 
secretory responses to cAMP at substimulatory (50 nM) concentrations of Ca 2 +. These results uggest that 
catecholamines do not inhibit insulin secretion solely by reducing B-cell adenylate cyclase activity, and imply 
that one site of action of noradrenaline is at a late stage in the secretory process. 
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1. INTRODUCTION 
Catecholamines exert a profound inhibition of 
insulin secretion in vivo, from perfused pancreas in 
vitro and from isolated islets of Langerhans, sug- 
gesting that circulating levels of the hormone 
adrenaline or the release of noradrenaline from 
sympathetic nerve terminals may play an impor- 
tant role in the physiological regulation of insulin 
secretion (reviews [1,2]). 
A number of mechanisms by which 
catecholamines could inhibit insulin secretion have 
been proposed, including effects on Ca 2+ handling 
[3,4], modulation of prostaglandin synthesis [5], 
and regulation of intracellular concentrations of 
cAMP [6,7]. The intracellular mechanisms of the 
inhibition are still unclear, but the ability of 
catecholamines to inhibit insulin release in 
response to a wide variety of secretagogues sug- 
gests an action at an important point in the 
secretory pathway. 
We have studied the involvement of Ca z+ and 
cAMP in the catecholamine inhibition of insulin 
secretion by comparing the effects of 
noradrenaline on insulin secretion from intact 
islets of Langerhans and from islets in which the 
cells have been permeabilised by high-voltage 
discharge to allow the introduction of ions and 
small molecules into the intracellular compart- 
ment. Electrically permeabilised islets do not re- 
spond to glucose [8] but secrete insulin in response 
to Ca 2÷ [91 or cAMP [10], and thus offer a useful 
model in which to study the involvement of these 
intracellular mediators in the control of insulin 
secretion. 
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2. MATERIALS AND METHODS 
Islets of Langerhans were isolated from rat pan- 
creas by collagenase digestion [11] and incubated 
for 60 min at 37°C in a bicarbonate-buffered (pH 
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7.4) physiological salt solution [12] containing 
2 mM glucose, 2 mM CaCI2 and 0.5 mg/ml  bovine 
serum albumin (BSA, fraction V). In experiments 
using intact islets, groups of three islets were in- 
cubated for 60 min at 37°C in 0.6 ml of the 
physiological salt solution containing the test 
substances of interest. In other experiments, islets 
were permeabilised by exposure to a high-intensity 
electric field [9]. Briefly, the islets were thoroughly 
washed in a Ca2+/EGTA buffer (permeation buf- 
fer) containing 140 mM K-glutamate, 15 mM 
Hepes, 7 mM MgSO4, 5 mM adenosine 
5'-tr iphosphate (ATP), 0.5 mg/ml BSA, 1-5 mM 
EGTA, pH 6.6, with CaCI2 added to produce a 
Ca 2÷ concentration of 50 nM, and permeabilised 
by 5 exposures to an electric field of 3.4 kV/cm. 
Groups of 10 permeabilised islets were incubated 
at 37°C for 30 min in 1.0 ml permeation buffer of 
various Ca 2÷ concentrations containing the test 
substances of interest. Insulin secretion from intact 
and permeabilised islets was measured by radioim- 
munoassay as described [13]. ATP, BSA, 
noradrenaline, yohimbine, cAMP and 2 ' -0 -  
dibutyryl adenosine 3' : 5'-cyclic monophosphate 
(db-cAMP) were obtained from Sigma (Poole, 
England). Ascorbic acid (100/zM) was included in 
all incubations to inhibit the oxidation of 
noradrenaline. Differences between means were 
assessed by analysis of variance or Student's un- 
paired t-test, as appropriate. 
3. RESULTS 
Noradrenaline caused a marked inhibition of 
glucose-stimulated insulin secretion from intact 
islets, and of Ca2+-induced insulin secretion from 
electrically permeabilised islets. Fig. 1 shows the ef- 
fects of noradrenaline (10/~M) on insulin secretion 
from intact islets in response to glucose (upper 
panel) and from permeabilised islets in response to 
Ca 2÷ (lower panel). Noradrenaline had no signifi- 
cant effects on the basal rate of insulin secretion by 
intact islets in 2 mM glucose, or on that of 
permeabilised islets in the presence of 50 nM Ca 2÷. 
However, the presence of 10/zM noradrenaline 
totally abolished the 10-fold increase in insulin 
secretion by intact islets in response to 20 mM 
glucose (fig.l, upper panel) and the secretory 
response of permeabilised islets to 10/~M Ca 2+ 
(fig.l, lower panel). 
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Fig.1. Noradrenaline inhibition of insulin secretion. 
Noradrenaline (10/zM, hatched bars) totally inhibited 
glucose-induced (20 mM) insulin secretion from intact 
islets (upper panel) and CaZ+-induced (10/zM) insulin 
secretion from electrically permeabilised islets (lower 
panel). Bars show mean _+ SE, n = 6-8. 
Inhibition of insulin secretion by noradrenaline 
was dose-related, as shown in fig.2. In permeabil- 
ised islets, 50°70 inhibition of the maximum 
Ca2÷-induced response was observed at a 
noradrenaline concentration of approx. 2.5/zM, 
while max imum inhibition of secretion was pro- 
duced by 10/~M noradrenaline (fig.2, upper 
panel). Inhibition of glucose-induced insulin secre- 
tion from intact islets showed a similar dose- 
response relationship, with 50°7o inhibition of 
secretion at around 2/zM noradrenaline and total 
inhibition of glucose-induced insulin secretion at 
noradrenaline concentrations of 5-10/zM (fig.2, 
lower panel). 
Noradrenaline inhibition of insulin secretion 
was antagonised by the oe2-adrenoreceptor an- 
tagonist yohimbine. In intact islets, 10/zM yohim- 
bine completely blocked the inhibition of 
glucose-induced insulin secretion by noradrenaline 
(20 mM glucose, 4.3 + 0.3 ng/islet per h; + 10/zM 
noradrenaline, 0.5 + 0.1; + 10/zM noradrenaline 
+ 10/zM yohimbine, 3.8 + 0.4, mean + SE, n = 
5). Similarly, in experiments using permeabilised 
islets 10/zM Ca 2÷ stimulated insulin secretion by 
254 _+ 33% (n = 9, p < 0.01), noradrenaline 
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Fig.2. Dose responsiveness of noradrenaline inhibition 
of insulin secretion. (Upper panel) Increasing 
concentrations of noradrenaline caused a dose-related 
inhibition of insulin secretion from electrically 
permeabilised islets incubated in the presence of 10/LM 
Ca 2÷. The open point shows basal secretion in the 
presence of 50 nM Ca 2÷ (mean _+ SE, n = 7). (Lower 
panel) Noradrenaline inhibition of insulin secretion 
from intact islets incubated in the presence of 20 mM 
glucose showed a similar dose responsiveness (mean +_ 
SE, n = 6). 
(10/zM) total ly inhibited Ca2÷-induced secretion 
(71 +_ 8% basal,  n = 9, N.S.)  and this inhibit ion 
was abol ished by the inclusion of  10/zM yohim- 
bine in the incubat ion buf fer  (270 _+ 27% basal,  n 
= 9, p < 0.01). 
The effects of  cAMP on insulin secretion f rom 
permeabi l ised islets are shown in fig.3 (upper 
panel), cAMP st imulated insulin secretion f rom 
electrically permeabi l ised islets at both sub- 
st imulatory (50 nM) and st imulatory (10/zM) con- 
centrat ions of  Ca 2÷. Noradrenal ine (10/~M) in- 
hibited the secretory response to 10/~M Ca 2÷ 
alone, and also reduced the insulin release evoked 
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Fig.3. Effects of cAMP on noradrenaline inhibition of 
insulin secretion. (Upper panel) Ca2+-induced insulin 
secretion from electrically permeabilised islets (o) was 
significantly 6O < 0.01) enhanced by .the presence of 
100/zM cAMP ( i ) .  Noradrenaline (10/zM) markedly 
inhibited insulin secretion in response to Ca z÷ alone 
(©). In the presence of 100/zM cAMP (t:]) 
noradrenaline had no effect on insulin secretion at sub- 
stimulatory Ca 2÷ concentration (50 nM), but 
significantly 6O < 0.01) inhibited secretion in the 
presence of 10,uM Ca 2+ (mean + SE, n = 9). (Lower 
panel) Glucose-induced insulin secretion from intact 
islets (20 mM, open bars) was enhanced by 5 mM db- 
cAMP, and totally inhibited by 10/~M noradrenaline. 
Noradrenaline also caused a significant reduction 6o < 
0.05) of the secretory response to db-cAMP plus 
glucose, but there was still a significant 6o < 0.01) 
stimulation of secretion above basal rates in the presence 
of 2 mM glucose (hatched bar, mean +__ SE, n = 4-6). 
by cAMP in the presence of  10/~M Ca z+. 
However,  noradrenal ine did not inhibit  insulin 
secretion in response to cAMP at sub-st imulatory 
concentrat ions of  Ca 2+ (+ cAMP,  224 + 38% 
basal; + cAMP + noradrenal ine,  226 _+ 46%, n = 
9). Fig.3 (lower panel) shows the results of  ex- 
per iments using intact islets in which glucose- 
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induced (20 mM) insulin secretion was enhanced in 
the presence of 5 mM db-cAMP. Noradrenaline 
(10/zM) completely inhibited glucose-stimulated 
insulin secretion (p > 0.2 vs 2 mM glucose con- 
trois) and significantly reduced (p < 0.05) the 
secretory response to db-cAMP in the presence of 
20 mM glucose. However, while noradrenaline 
totally abolished glucose-induced secretion, it did 
not completely inhibit the secretory response to db- 
cAMP, since a 3-fold increase in insulin release 
above basal levels (p < 0.01) was observed in the 
presence of both noradrenaline and db-cAMP. 
4. DISCUSSION 
Despite numerous reports that catecholamines 
inhibit insulin secretion from pancreatic B-cells 
(see [1,2]) the intracellular mechanisms of this in- 
hibition remain obscure. The catecholamine in- 
hibition of secretion is thought o be a direct effect 
on B-cells [7,14] and to be mediated by 
cez-adrenoreceptors [15,16], as confirmed in the 
present studies by the abolition of the inhibitory 
effects of noradrenaline by the o~2-receptor an- 
tagonist, yohimbine. In addition to suppressing 
glucose-induced insulin secretion from intact islets, 
noradrenaline also had marked inhibitory effects 
on Ca2+-induced secretion from electrically 
permeabilised islets, as has previously been 
reported in studies using digitonin-treated islets 
[17]. The similar inhibitory effects of 
noradrenaline on insulin secretion from both intact 
and permeabilised islets in the present study, and 
the antagonism of these effects by yohimbine, sug- 
gest a similar mode of action of the catecholamine 
in the two systems. These also suggest that the elec- 
trically permeabilised islet is a valid model for 
studying the noradrenaline inhibition of insulin 
secretion. 
A number of conclusions can be drawn from the 
catecholamine inhibition of CaZ+-induced insulin 
secretion from permeabilised islets. Firstly, elec- 
trically permeabilised islets retain functional 
ce2-adrenoreceptors which are still linked to their 
effector system. Secondly, the intracellular effec- 
tor system through which noradrenaline inhibits 
insulin secretion can function in permeabilised 
cells in which the intracellular environment is in 
equilibrium with an extracellular medium of de- 
fined composition. Thirdly, the noradrenaline in- 
hibition of insulin secretion from permeabilised 
islets in the presence of a maximum stimulatory 
concentration of Ca z÷ [9] suggests that 
noradrenaline reduces the capacity of B-cells to 
respond to Ca 2÷, and therefore implies that 
noradrenaline does not act primarily by affecting 
cellular Ca z+ handling but at some later stage in 
the secretory process. A similar conclusion has 
recently been drawn from less direct studies using 
intact tissue. Thus, in intact islets, the effects of 
catecholamines on Ca 2÷ uptake [16] or efflux [18] 
could be dissociated from the inhibition of insulin 
secretion, while fluorescence measurements of 
cytosolic Ca 2÷ in insulin-secreting tumour cells 
demonstrated that ce2-agonists could inhibit insulin 
secretion without measurably affecting in- 
tracellular concentrations of Ca 2÷ [19]. 
In other tissues ce2-agonists can act by inhibiting 
adenylate cyclase and thus reducing intracellular 
concentrations of cAMP [20]. It has been sug- 
gested that a similar mechanism is involved in the 
adrenergic inhibition of insulin secretion since 
cAMP is thought to play an important role in 
regulating the magnitude of the B-cell secretory 
response (review [21]). I_n support of such a 
mechanism, catecholamines have been reported to 
inhibit adenylate cyclase activity in islet 
homogenates [22,23] and to decrease the total 
cAMP content of isolated islets [24,25] and B-cells 
[7]. However, the effects of o~2-agonists on islet 
cAMP are variable and do not always parallel the 
inhibitory effects on insulin secretion [26,27]. Fur- 
thermore, there have been several reports that 
catecholamines inhibit insulin secretion in the 
presence of membrane-permeable analogues of 
cAMP [3,15,16], as was confirmed in the present 
studies using intact islets, suggesting that the in- 
hibition of secretion cannot be solely attributed to 
a decrease in intracellular cAMP. Note, however, 
that in our experiments the noradrenaline inhibi- 
tion of secretion in response to db-cAMP plus 
glucose was only partial, even at a concentration of
noradrenaline well in excess of that required to in- 
hibit totally secretion in response to glucose alone. 
Similar results have also been reported in other re- 
cent studies [16] in which the secretory responses to 
db-cAMP were only abolished at concentrations of
noradrenaline at least an order of magnitude 
greater than those required to inhibit totally 
glucose-induced insulin secretion, in contrast to 
142 
Volume 219, number 1 FEBS LETTERS July 1987 
earlier reports in which similar concentrations of 
catecholamines totally inhibited db-cAMP- 
induced secretion from intact islets [3,15]. 
The conclusion that decreases in intracellular 
cAMP cannot fully account for the inhibition of 
insulin secretion was further supported by our 
studies in permeabilised islets in which the in- 
tracellular concentrations of cAMP could be 
precisely controlled. Thus, supplying a stimulatory 
concentration of cAMP to the intracellular com- 
partment did not reverse the noradrenaline inhibi- 
tion of Ca2+-induced insulin secretion, suggesting 
the involvement of factors other than cAMP in the 
inhibitory mechanism under these conditions. 
However, the small but significant secretory 
responses of permeabilised islets to cAMP at sub- 
stimulatory Ca 2+ concentrations were not affected 
by noradrenaline, perhaps suggesting that 
catecholamines preferentially inhibit the normal 
secretory responses of permeabilised B-cells to 
Ca 2+, rather than to cAMP. cAMP is generally 
thought not to be an initiator of insulin secretion, 
but to modulate the magnitude of the B-cell 
secretory response to primary stimuli (see [21]), 
perhaps by increasing the sensitivity of the 
secretory process to Ca 2+ [10,28]. It is therefore 
slightly surprising that cAMP stimulated insulin 
secretion from noradrenaline-treated permeabil- 
ised islets which no longer responded to Ca 2+. It 
may be that the responsiveness of noradrenaline- 
treated permeabilised islets to cAMP reflects two 
opposing effects on the secretory process, with 
cAMP increasing, and noradrenaline decreasing, 
the sensitivity of the secretory process to Ca 2+. 
Alternatively, it may be that a minor component of 
the secretory response to cAMP is independent of 
Ca 2+ and is therefore unaffected by the 
catecholamine inhibition of Ca2+-induced 
secretion. 
In conclusion, our experiments using electrically 
permeabilised islets suggest that direct introduc- 
tion of Ca 2+ or cAMP into the cytosolic compart- 
ment does not fully relieve the catecholamine 
inhibition of insulin secretion, implying that at 
least one component of the inhibition occurs at a 
stage of the secretory pathway beyond changes in 
intracellular Ca 2+ or cAMP. The mechanisms by 
which the adrenergic receptor-mediated inhibition 
of insulin secretion can occur at a late stage of the 
secretory pathway merit further investigation. 
ACKNOWLEDGEMENTS 
Financial assistance from the Medical Research 
Council and the British Diabetic association is 
gratefully acknowledged. J M.F. was an SERC- 
CASE student. We thank the late Professor P.F. 
Baker for helpful discussions. 
REFERENCES 
[l] Miller, R.E. (1981) Endocr. Rev. 2, 471-494. 
[2] Ahren, B., Taborsky, G.J. jr and Porte, D. jr 
(1986) Diabetologia 29, 827-836. 
[3] Malaisse, W.J., Brisson, G. and Malaisse-Lagae, 
F. (1970) J. Lab. Clin. Med. 76, 895-902. 
[4] Lorenz, R., Sharp, R. and Burr, I.M. (1979) 
Diabetes 28, 52-55. 
[5] Metz, S.A. and Roberston, R.P. (1980) Am. J. 
Physiol. 239, E490-E500. 
[6] Yamazaki, S., Katada, T. and Ui, M. (1982) Mol. 
Pharmacol. 21, 648-653. 
[7] Schuit, F.C. and Pipeleers, D.G. (1986) Science 
232, 875-877. 
[8] Jones, P.M. and Howell, S.L. (1986) in: Biophysics 
of the Pancreatic B Cell (Atwater, I. et al. eds) 
Plenum, New York. 
[9l Jones, P.M., Stutchfield, J. and Howell, S.L. 
(1985) FEBS Lett. 191, 102-106. 
[10] Jones, P.M., Fyles, J.M. and Howell, S.L. (1986) 
FEBS Lett. 205, 205-209. 
[Ill Howell, S.L. and Taylor, K.W. (1968) Biochem. J. 
108, 17-24. 
[12] Gey, G.O. and Gey, M.L. (1936)Am. J. Cancer 27, 
45-76. 
[13] Hii, C.S.T., Stutchfield, J. and Howell, S.L. (1986) 
Biochem. J. 233, 287-289. 
[14] Fyles, J.M., Cawthorne, M.A. and Howell, S.L. 
(1987) Biosci. Rep., in press. 
[15] Nakaki, T., Nakadate, T., Yamamoto, S. and 
Kato, R. (1983) Life Sci. 23, 191-195. 
[16] Morgan, N.G. and Montague, W. (1985) Biochem. 
J. 226, 571-576. 
[17] Tamagawa, T., Niki, I., Niki, H. and Niki, A. 
(1985) Biomed. Res. 6, 429-432. 
[18] Morgan, N.G., Rumford, G.M. and Montague, W. 
(1985) Biosci. Rep. 5, 1053-1060. 
[19] Ullrich, S. and Wollheim, C.B. (1985) Mol. 
Pharmacol. 28, 100-106. 
[20] Exton, J.H. (1985) Am. J. Physiol. 248, 
E633-E647. 
[21] Malaisse, W.J. and Malaisse-Lagae, F. (1984) 
Experientia 40, 1068-1075. 
[22] Howell, S.L. and Montague, W. (1973) Biochim. 
Biophys. Acta 320, 44-52. 
143 
Volume 219, number 1 FEBS LETTERS July 1987 
[23] Kuo, W.-N., Hodgins, D.S. and Kuo, J.F. (1973) 
J. Biol. Chem. 248, 2705-2711. 
[24] Katada, T. and Ui, M. (1981) J. Biochem. 89, 
979-990. 
[25] Garcia-Morales, P., Dufrane, S.P., Sener, A., 
Valverde, I. and Malaisse, W.J. (1984) Biosci. Rep. 
4, 511-521. 
[26] Rabinovitch, A., Cerasi, E. and Sharp, G.W.G. 
(1978) Endocrinology 102, 1733-1740. 
[27] Ullrich, S. and Wollheim, C.B. (1984) J. Biol. 
Chem. 259, 4111-4115. 
[28] Hughes, S.J., Christie, M.R. and Ashcroft, S.J.H. 
(1987) Mol. Cell. Endocr. 50, 231-236. 
144 
